St. Jude Medical
The 10-second takeaway
For the quarter ended Dec. 29 (Q4), St. Jude Medical met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank slightly and GAAP earnings per share grew.
Gross margins increased, operating margins expanded, net margins dropped.
St. Jude Medical reported revenue of $1.37 billion. The 16 analysts polled by S&P Capital IQ predicted sales of $1.37 billion on the same basis. GAAP reported sales were 2.5% lower than the prior-year quarter's $1.41 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.92. The 24 earnings estimates compiled by S&P Capital IQ predicted $0.89 per share. GAAP EPS of $0.39 for Q4 were 2.6% higher than the prior-year quarter's $0.38 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 72.9%, 150 basis points better than the prior-year quarter. Operating margin was 28.5%, 1,070 basis points better than the prior-year quarter. Net margin was 8.7%, 20 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $1.40 billion. On the bottom line, the average EPS estimate is $0.89.
Next year's average estimate for revenue is $5.64 billion. The average EPS estimate is $3.61.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on St. Jude Medical is outperform, with an average price target of $42.34.
Can your portfolio provide you with enough income to last through retirement? You'll need more than St. Jude Medical. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add St. Jude Medical to My Watchlist.